CUSIP 359664109 · who reports it, how much, and how much it matters to them
20 of the 720 hedge fund managers we track reported shares of Fulgent Genetics, Inc. (Nasdaq: FLGT) on Form 13F for 30 June 2026. Between them they reported USD 60m. The largest position belongs to Diametric Capital, at USD 14m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Diametric Capital2 funds on PPLI.com | USD 14m | 1.5% |
| 2 | Two Sigma Investments35 funds on PPLI.com | USD 8.2m | 0.0% |
| 3 | Millennium Management6 funds on PPLI.com | USD 6.6m | 0.0% |
| 4 | D. E. Shaw & Co.15 funds on PPLI.com | USD 6m | 0.0% |
| 5 | POINT72 Asset Management17 funds on PPLI.com | USD 4.3m | 0.0% |
| 6 | Medina Value Partners2 funds on PPLI.com | USD 4m | 0.8% |
| 7 | Citadel Advisors32 funds on PPLI.com | USD 3.6m | 0.0% |
| 8 | Almitas Capital2 funds on PPLI.com | USD 2.2m | 0.5% |
| 9 | Tudor Investment Corporation10 funds on PPLI.com | USD 1.7m | 0.0% |
| 10 | Caxton Associates6 funds on PPLI.com | USD 1.3m | 0.0% |
| 11 | Balyasny Asset Management25 funds on PPLI.com | USD 1.1m | 0.0% |
| 12 | Prelude Capital Management9 funds on PPLI.com | USD 1.1m | 0.1% |
| 13 | Moore Capital Management7 funds on PPLI.com | USD 992,000 | 0.0% |
| 14 | Exoduspoint Capital Management7 funds on PPLI.com | USD 966,000 | 0.0% |
| 15 | Brevan Howard Capital Management39 funds on PPLI.com | USD 920,000 | 0.0% |
| 16 | Boothbay Fund Management2 funds on PPLI.com | USD 877,000 | 0.0% |
| 17 | Entrypoint Capital1 fund on PPLI.com | USD 575,000 | 0.1% |
| 18 | Persistent Asset Partners10 funds on PPLI.com | USD 488,000 | 0.1% |
| 19 | Atom Investors1 fund on PPLI.com | USD 421,000 | 0.0% |
| 20 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 207,000 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Diametric Capital | USD 14m | 1.5% |
| 2 | Medina Value Partners | USD 4m | 0.8% |
| 3 | Almitas Capital | USD 2.2m | 0.5% |
| 4 | Persistent Asset Partners | USD 488,000 | 0.1% |
| 5 | Entrypoint Capital | USD 575,000 | 0.1% |
| 6 | Prelude Capital Management | USD 1.1m | 0.1% |
| 7 | Atom Investors | USD 421,000 | 0.0% |
| 8 | Caxton Associates | USD 1.3m | 0.0% |
| 9 | Moore Capital Management | USD 992,000 | 0.0% |
| 10 | Boothbay Fund Management | USD 877,000 | 0.0% |
Fulgent Genetics, Inc. trades under the symbol FLGT on the Nasdaq. Its CUSIP, the code used on Form 13F, is 359664109.
20 of the 720 hedge fund managers PPLI.com tracks reported Fulgent Genetics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Diametric Capital (USD 14m), Two Sigma Investments (USD 8.2m), Millennium Management (USD 6.6m), D. E. Shaw & Co. (USD 6m) and POINT72 Asset Management (USD 4.3m).
20 managers in our coverage reported it, and between them they run 258 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Diametric Capital, where the position was 1.5% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Fulgent Genetics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.